作者：
Figtree, Gemma A. [1]
;
Broadfoot, Keith [2]
;
Casadei, Barbara [3]
;
Califf, Robert [4]
;
Crea, Filippo [5]
;
Drummond, Grant R. [6]
;
Freedman, Jane E. [7]
;
Guzik, Tomasz J. [8]
;
Harrison, David [9]
;
Hausenloy, Derek J. [10]
;
Hill, Joseph A. [11]
;
Januzzi, James L. [12]
;
Kingwell, Bronwyn A. [13]
;
Lam, Carolyn S. P. [14]
;
MacRae, Calum A. [15]
;
Misselwitz, Frank [16]
;
Miura, Tetsuji [17]
;
Ritchie, Rebecca H. [18]
;
Tomaszewski, Maciej [19]
;
Wu, Joseph C. [20]
;
Xiao, Junjie [21]
;
Zannad, Faiez [22]
作者单位：
Univ Oxford, Radcliffe Dept Med, Div Cardiovasc Med, Oxford, England
[1]
La Trobe Univ, Ctr Cardiovasc Biol & Dis Res, Melbourne, Vic, Australia
[2]
Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3]
Catholic Univ, Rome, Italy
[4]
Sapporo Med Univ, Dept Cardiovasc Renal & Metab Med, Sapporo, Hokkaido, Japan
[5]
Univ Massachusetts, Med Sch, Cardiovasc Res, Amherst, MA 01003 USA
[6]
Stanford Cardiovasc Inst, Stanford, CA USA
[7]
Univ Texas Southwestern, Dallas, TX USA
[8]
CSL Ltd, Melbourne, Vic, Australia
[9]
Univ Lorraine, CHRU Nancy, INI CRCT, INSERM CIC 1493, Nancy, France
[10]
Natl Heart Ctr Singapore, Singapore, Singapore
[11]
Verily, San Francisco, CA USA
[12]
Shanghai Univ, Sch Life Sci, Inst Cardiovasc Sci, Cardiac Regenerat & Ageing Lab, Shanghai 200444
[13]
Vanderbilt Univ, Sch Med, Clin Pharmacol, Nashville, TN 37212 USA
[14]
Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA
[15]
Natl Heart Fdn Australia, Clin Comm, Melbourne, Vic, Australia
[16]
Duke Natl Univ Singapore, Signat Res Program, NUS Med Sch, Cardiovasc & Metab Disorders Program
[17]
Bayer AG, Pharmaceut Div, Wuppertal, Germany
[18]
Univ Manchester, Div Cardiovasc Sci, Fac Biol Med & Hlth, Manchester, Lancs, England
[19]
Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[20]
Monash Univ, Drug Discovery Biol, Monash Inst Pharmaceut Sci, Parkville Campus, Parkville, Vic
[21]
Univ Sydney, Royal North Shore Hosp, Kolling Inst, Sydney, NSW, Australia
[22]
发布时间
2021-08-04
换一批
